Immunotherapy

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thursday, October 21, 2021 - 9:30pm

Each stock option has an exercise price of$12.03,the closing price of PDS Biotechs common stock on October 19, 2021.

Key Points: 
  • Each stock option has an exercise price of$12.03,the closing price of PDS Biotechs common stock on October 19, 2021.
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.
  • The companys pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers.
  • Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance.

FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE BREAST CANCER PARTNERSHIP RECEIVES NATIONAL ACCREDITATION

Thursday, October 21, 2021 - 8:23pm

Its board membership includes professionals from 20 national organizations that reflect the full spectrum of breast care.

Key Points: 
  • Its board membership includes professionals from 20 national organizations that reflect the full spectrum of breast care.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.
  • Central Florida Cancer Institute is a cancer treatment facility established in 1999 by Dr. Randy Heysek in Davenport, Florida.

Longbow Immunotherapy Launches ReACT, A Novel CAR-T Platform Targeting Solid Tumors

Thursday, October 21, 2021 - 2:00pm

Longbow Immunotherapy, a newly formed biotech advancing solid tumor therapy, announced its formation and exclusive license of the ReACT platform from the Versiti Blood Research Institute.

Key Points: 
  • Longbow Immunotherapy, a newly formed biotech advancing solid tumor therapy, announced its formation and exclusive license of the ReACT platform from the Versiti Blood Research Institute.
  • ReACT (Re-energized adoptive cell transfer), combines CAR-T cell therapy with microbial immunotherapies, such as bacteria and oncolytic viruses, to synergistically treat solid tumors.
  • Its advantages include modification of the tumor microenvironment, localized activity, broad targeting of tumor antigens, and prevention of T cell exhaustion.
  • Longbow also plans to extend the application of ReACT beyond initial bladder cancer uses, as ReACT T cells can be engineered to recognize and synergize with any bacterial immunotherapy or oncolytic virus targeting solid tumors.

Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting

Thursday, October 21, 2021 - 2:00pm

The full abstract is scheduled to be available on the SITC website on November 9, 2021.

Key Points: 
  • The full abstract is scheduled to be available on the SITC website on November 9, 2021.
  • HER2 is a receptor tyrosine kinase that is overexpressed on many solid tumors, including breast, gastric, and bladder cancers.
  • AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain.
  • Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers.

Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting

Thursday, October 21, 2021 - 1:00pm

The poster highlights recent preclinical data for the companys most advanced product candidate, IGV-001.

Key Points: 
  • The poster highlights recent preclinical data for the companys most advanced product candidate, IGV-001.
  • The data elucidate potential mechanisms for the observed immune-stimulating and tumor-suppressing activity of IGV-001 seen in the Phase 1 clinical study for glioblastoma.
  • Were pleased to share new insights into the mechanism of action of IGV-001, which are supportive of the clinical efficacy data weve previously reported, said John Furey, Chief Executive Officer.
  • Imvaxs portfolio includes several programs designed to stimulate a patients immune system against the entire antigen signature of their tumor.

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

Thursday, October 21, 2021 - 12:30pm

The issue is not specific to the PDS0101 trial and is unrelated to any safety or efficacy concerns with the triple combination.

Key Points: 
  • The issue is not specific to the PDS0101 trial and is unrelated to any safety or efficacy concerns with the triple combination.
  • The timing of clinical data resulting from this trial is not expected to be affected by the recruitment suspension.
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.
  • PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

Thursday, October 21, 2021 - 12:00pm

Any outstanding units of Big Cypress, consisting of shares of Big Cypress common stock and warrants to purchase Big Cypress common stock, will automatically separate into the equivalent number of common stock and warrants of the Combined Company upon the consummation of the Business Combination.

Key Points: 
  • Any outstanding units of Big Cypress, consisting of shares of Big Cypress common stock and warrants to purchase Big Cypress common stock, will automatically separate into the equivalent number of common stock and warrants of the Combined Company upon the consummation of the Business Combination.
  • On October 20, 2021, the stockholders of Big Cypress voted in favor of a proposal to approve the Business Combination at the special meeting of stockholders.
  • Investors and security holders of Big Cypress are advised to read the proxy statement/prospectus in connection with Big Cypress' solicitation of proxies for its special meeting of stockholders to be held to approve the proposed business combination (and related matters) because the proxy statement/prospectus contains important information about the proposed business combination and the parties to the proposed business combination.
  • Big Cypress, SAB and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Big Cypress' stockholders in connection with the proposed business combination.

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

Thursday, October 21, 2021 - 12:00pm

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, announced the first patient has been treated in an investigator-initiated, open-label Phase 2 study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3rd line recurrent small-cell lung cancer (SCLC) who failed checkpoint inhibitors and platinum-based chemotherapy. Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. This Phase 2 study, to be conducted through the Big Ten Cancer Research Consortium in 7 U.S. clinical centers, comes after the successful completion of the Phase 1 dose escalation study portion of this Phase 1/2 study.

Key Points: 
  • In the Phase 1 study, plinabulin combination was able to induce tumor responses in patients who had progressed on platinum and checkpoint inhibitors, with 43% ORR (3 partial responses with tumor reduction >50%).
  • This Phase 2 study, to be conducted through the Big Ten Cancer Research Consortium in 7 U.S. clinical centers, comes after the successful completion of the Phase 1 dose escalation study portion of this Phase 1/2 study.
  • For patients with extensive stage SCLC who failed chemo and checkpoint inhibitors, effective treatment options are limited.
  • In the Phase 1 study, the addition of plinabulin to nivolumab + ipilimumab was able to induce tumor responses in patients who failed chemotherapy and checkpoint inhibitors with ORR at 43%, double the ORR of nivolumab + ipilimumab in Checkmate 032.

Cancer Immunotherapy Market - Global Forecast up to 2026: Focus on Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors, Immunomodulators - ResearchAndMarkets.com

Thursday, October 21, 2021 - 10:36am

The "Cancer Immunotherapy Market by Product Type, Application, End Users, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Immunotherapy Market by Product Type, Application, End Users, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Cancer Immunotherapy Market is projected to grow at the rate of 9.7% CAGR by 2026.
  • Immunotherapy is a type of treatment to cure cancer that utilizes a few parts of a person's immune system to fight cancer.
  • With the considerable pressure of increasing cancer cases and the side effects of other therapies, cancer immunotherapy has exhibited tremendous potential over the past few years.

OncoSec Provides Business Update

Wednesday, October 20, 2021 - 9:02pm

We are excited to update the community at SITC 2021."

Key Points: 
  • We are excited to update the community at SITC 2021."
  • OncoSec will make the poster available on its website following publication at SABCS 2021.
  • OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.
  • TAVO is a trademark of OncoSec Medical Incorporated.